• Product nameAnti-VEGFA antibody [6D3]
    See all VEGFA primary antibodies
  • Description
    Mouse monoclonal [6D3] to VEGFA
  • SpecificityRecognizes vascular endothelial growth factor A precursor (VEGFA).
  • Tested applicationsSuitable for: WB, ELISA, Neutralisingmore details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Recombinant full length protein corresponding to Human VEGFA.

  • Positive control
    • Recombinant VEGF165.


Our Abpromise guarantee covers the use of ab36424 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB Use a concentration of 2 - 10 µg/ml. Predicted molecular weight: 45 kDa.
ELISA Use a concentration of 1 - 15 µg/ml.
Neutralising Use at an assay dependent dilution. Has been shown to block the VEGFA induced proliferation of ACE cell at a 1:6 molar ratio of ligand to antibody. Inhibits the binding of VEGF A to the VEGF receptors 1 (Flt-1) and 2 (KDR).


  • FunctionGrowth factor active in angiogenesis, vasculogenesis and endothelial cell growth. Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. Binds to the FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin. NRP1/Neuropilin-1 binds isoforms VEGF-165 and VEGF-145. Isoform VEGF165B binds to KDR but does not activate downstream signaling pathways, does not activate angiogenesis and inhibits tumor growth.
  • Tissue specificityIsoform VEGF189, isoform VEGF165 and isoform VEGF121 are widely expressed. Isoform VEGF206 and isoform VEGF145 are not widely expressed.
  • Involvement in diseaseDefects in VEGFA are a cause of susceptibility to microvascular complications of diabetes type 1 (MVCD1) [MIM:603933]. These are pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. Diabetic retinopathy remains the major cause of new-onset blindness among diabetic adults. It is characterized by vascular permeability and increased tissue ischemia and angiogenesis.
  • Sequence similaritiesBelongs to the PDGF/VEGF growth factor family.
  • Cellular localizationSecreted. VEGF121 is acidic and freely secreted. VEGF165 is more basic, has heparin-binding properties and, although a signicant proportion remains cell-associated, most is freely secreted. VEGF189 is very basic, it is cell-associated after secretion and is bound avidly by heparin and the extracellular matrix, although it may be released as a soluble form by heparin, heparinase or plasmin.
  • Information by UniProt
  • Database links
  • Alternative names
    • MGC70609 antibody
    • MVCD1 antibody
    • Vascular endothelial growth factor A antibody
    • vascular endothelial growth factor antibody
    • Vascular permeability factor antibody
    • VEGF A antibody
    • Vegf antibody
    • VEGF-A antibody
    • VEGF120 antibody
    • Vegfa antibody
    • VEGFA_HUMAN antibody
    • VPF antibody
    see all

References for Anti-VEGFA antibody [6D3] (ab36424)

This product has been referenced in:
  • Hudson EP  et al. Multiplex epitope mapping using bacterial surface display reveals both linear and conformational epitopes. Sci Rep 2:706 (2012). Read more (PubMed: 23050090) »
  • Rossi SL  et al. Histological and functional benefit following transplantation of motor neuron progenitors to the injured rat spinal cord. PLoS One 5:e11852 (2010). Blocking ; Human . Read more (PubMed: 20686613) »

See all 2 Publications for this product

Product Wall

Thank you for your reply.

These products were created using full length VEGF recombinant proteins. We are not currently aware of the exact epitopes recognized by the antibodies. I did run alignments of the human VEGF protein to both rat an...

Read More